We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52M
AUM Growth
-$6.16B
Cap. Flow
-$249M
Cap. Flow %
-4,517.93%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
PGNY icon
Progyny
PGNY
+$22.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
76
Regeneron Pharmaceuticals
REGN
$72.9B
$13.1K 0.24%
+22,200
New +$14.4M
ISEE
77
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$13.1K 0.24%
+1,361,400
New +$17.1M
IMA
78
ImageneBio Inc
IMA
$65.5M
$13K 0.24%
244,495
– –
NXTC icon
79
NextCure
NXTC
$22.1M
$12.7K 0.23%
225,918
– –
SGFY
80
DELISTED
Signify Health, Inc.
SGFY
$12.4K 0.23%
900,000
+279,300
+45% +$3.93M
TBPH icon
81
Theravance Biopharma
TBPH
$875M
$12.4K 0.22%
1,370,250
-1,884,463
-58% -$17.4M
VTGN icon
82
VistaGen Therapeutics
VTGN
$9.55M
$11.8K 0.21%
447,376
+17,067
+4% +$603K
ETNB
83
DELISTED
89bio
ETNB
$11.8K 0.21%
3,658,869
– –
KZR
84
DELISTED
Kezar Life Sciences
KZR
$11.7K 0.21%
+141,990
New +$12.5M
MIST icon
85
Milestone Pharmaceuticals
MIST
$133M
$11.2K 0.2%
1,817,521
-766,300
-30% -$4.71M
MREO
86
Mereo BioPharma
MREO
$49.4M
$10.9K 0.2%
2,601,468
-7,553,342
-74% -$5.85M
DHR.PRB
87
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
– –
0
– –
IRON icon
88
Disc Medicine
IRON
$2.85B
$9.85K 0.18%
194,207
– –
CMMB
89
Chemomab Therapeutics
CMMB
$10.5M
$9.54K 0.17%
644,544
– –
TERN
90
DELISTED
Terns Pharmaceuticals
TERN
$9.4K 0.17%
3,791,204
– –
ORIC icon
91
Oric Pharmaceuticals
ORIC
$1.23B
$9.35K 0.17%
2,087,568
– –
ERAS icon
92
Erasca
ERAS
$6.3B
$9.29K 0.17%
1,667,693
– –
JNCE
93
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$8.88K 0.16%
2,928,900
+69,000
+2% +$336K
SGEN
94
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$8.85K 0.16%
+50,000
New +$7.21M
CGEM icon
95
Cullinan Oncology
CGEM
$1.07B
$8.6K 0.16%
670,787
– –
XBI icon
96
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$8.3K 0.15%
111,800
– –
FUSN
97
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$8.03K 0.15%
3,224,770
– –
JBIO
98
Jade Biosciences
JBIO
$1.2B
$7.48K 0.14%
13,674
-896
-6% -$428K
DMRA
99
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.81B
$7.08K 0.13%
163,637
– –
SYBX
100
DELISTED
Synlogic
SYBX
$6.93K 0.13%
402,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52M, down 100% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed withdrew a net $249M in Q2 2022, closing 15 positions and reducing 36 holdings. Its most notable exit was DexCom, an estimated $76.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Progyny worth $18.2K.

  • OrbiMed's largest Q2 2022 buy was Progyny: 625,000 shares worth $18.2K.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52M portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 100% quarter-over-quarter to $5.52M.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.